The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)

PRESERVE-003: Phase 3, two-stage, randomized study of ONC-392 versus docetaxel in metastatic non-small cell lung cancers that progressed on PD-1/PD-L1 inhibitors.

Mark A.  Socinski

Honoraria - Arcus Biosciences; AstraZeneca; Bayer; Bristol-Myers Squibb; Coherus Biosciences; G1 Therapeutics; Genentech; Gilead Sciences; GlaxoSmithKline; GlaxoSmithKline; Gritstone Bio; Guardant Health; Janssen Oncology; Jazz Pharmaceuticals; Lilly; Merck; Mirati Therapeutics; Novartis; Regeneron; Roche/Genentech; Spectrum Pharmaceuticals; Takeda

Consulting or Advisory Role - Genentech; Janssen; Lilly; Spectrum Pharmaceuticals

Speakers' Bureau - Amgen; AstraZeneca; Blueprint Medicines; Bristol-Myers Squibb; G1 Therapeutics; Genentech; Guardant Health; Janssen Oncology; Jazz Pharmaceuticals; Lilly; Merck; Sanofi/Regeneron; Takeda

Research Funding - AstraZeneca/MedImmune (Inst); Daiichi Sankyo/Astra Zeneca (Inst); Genentech (Inst); Mirati Therapeutics (Inst); Spectrum Pharmaceuticals (Inst)

Kai  He

Consulting or Advisory Role - AstraZeneca; Bristol-Myers Squibb; Geneplus; Iovance Biotherapeutics; Lyell Immunopharma; Mirati Therapeutics; Perthera

Research Funding - Abbvie (Inst); Adaptimmune (Inst); Amgen (Inst); Bristol-Myers Squibb (Inst); Genentech/Roche (Inst); GlaxoSmithKline (Inst); Iovance Biotherapeutics (Inst); Mirati Therapeutics (Inst); Oncoc4 (Inst)

Tianhong  Li

Honoraria - Tempus

Research Funding - Abbvie (Inst); Astellas Pharma (Inst); Astellas Pharma (Inst); AstraZeneca (Inst); AtlasMedx (Inst); Genentech (Inst); Hengrui Therapeutics (Inst); Jounce Therapeutics (Inst); LabyRx Immuno-Oncology (Inst); Lung Cancer Mutation Consortium (Inst); Merck (Inst); Novartis (Inst); Nvigen (Inst); OncoImmune/OncoC4 (Inst); Pfizer (Inst); RasCal (Inst); Tempus (Inst)

Dan  Chen

Employment - OncoC4

Leadership - OncoC4

Stock and Other Ownership Interests  - OncoC4

Kun  He

Employment - R & G US

Consulting or Advisory Role - OncoC4

Yang  Liu

Employment - OncoC4; OncoC4 (I)

Leadership - OncoC4; OncoC4 (I)

Stock and Other Ownership Interests  - OncoC4; OncoC4 (I)

Patents, Royalties, Other Intellectual Property - Patent on ONC-392; Patent on ONC-392 (I)

Pan  Zheng

Employment - OncoC4

Leadership - OncoC4

Stock and Other Ownership Interests  - OncoC4

Patents, Royalties, Other Intellectual Property - Patent on ONC-392, a new next generation anti-CTLA-4 antibody.